In this study, the investigates try to confirm the hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in acute coronary syndrome patients with diabetes. Totally 40 ACS patients with diabetes will be divided into 2 groups randomly after PCI for one month. Group 1 will be treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group; Group2 will be treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment. The platelets function will be tested in VASP and TEG methods at 1 and 2 months after PCI as the primary endpoints.The clinical events will be observed 12 months after PCI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
Aspirin
shanghai Tongren hospital
Shanghai, China
RECRUITINGchanges of PRI detected by VASP
platelet reactivity index (PRI) detected by VASP (Vasodilator Stimulated Phosphoprotein) Phosphoprotein)
Time frame: changes of PRI from baseline (1 months after index PCI) to 2 months after index PCI
changes of Maximum Amplitude (MA) detected by TEG
Maximum Amplitude (MA) detected by TEG(Thromboelastography)
Time frame: changes of MA from baseline (1 months after index PCI) to 2 months after index PCI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.